Weiss Multi Strategy Advisers LLC Uni Qure N.V. Transaction History

Weiss Multi Strategy Advisers LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$11.12 - $22.2 $44,368 - $88,578	-3,990 Reduced 6.9%	53,877 $617,000
Q1 2023 May 15, 2023	BUY	$18.7 - $23.07 $364,967 - $450,257	19,517 Added 50.89%	57,867 $1.17 Million
Q4 2022 Feb 14, 2023	BUY	$18.12 - $27.32 $694,902 - $1.05 Million	38,350 New	38,350 $869,000
Q3 2020 Nov 16, 2020	SELL	$35.98 - $47.66 $161,370 - $213,755	-4,485 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$45.06 - $67.74 $6,894 - $10,364	153 Added 3.53%	4,485 $202,000
Q1 2020 May 15, 2020	BUY	$40.01 - $73.97 $173,323 - $320,438	4,332 New	4,332 $206,000
Q4 2017 Feb 14, 2018	SELL	$9.47 - $19.59 $511,380 - $1.06 Million	-54,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$7.7 - $9.6 $415,800 - $518,400	54,000	54,000 $518,000

153

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $266M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Weiss Multi Strategy Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Weiss Multi Strategy Advisers LLC with notifications on news.